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Abstract: Since their introduction in the 1980s, 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase inhibitors (statins) have emerged as the one of the best-selling medica-
tion classes to date, with numerous trials demonstrating powerful efﬁ  cacy in preventing car-
diovascular outcomes. As our understanding of low-density lipoprotein cholesterol (LDL-C) 
and atherosclerosis continues to grow, the concept of ‘lower is better’ has corresponded with a 
‘more is better’ approach to statin-based therapy. This review provides a detailed understanding 
of the clinical efﬁ  cacy and safety of statins with a particular emphasis on the third generation 
drug, rosuvastatin.
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Introduction
In 1976, the Japanese scientist Akira Endo identiﬁ  ed a fungal metabolite that blocks 
cholesterol synthesis by inhibiting the enzyme 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase, resulting in the ﬁ  rst ‘statin’ agent, mevastatin (Endo 2004). In 
addition to blocking this key enzyme involved in cholesterol synthesis, statins possess 
numerous pleiotropic properties including: (i) nitric oxide-mediated improvement of 
endothelial dysfunction and upregulation of endothelin-1 expression; (ii) antioxidant 
effects; (iii) anti-inﬂ  ammatory properties; (iv) inhibition of cell proliferation with 
anticarcinogenic actions in animals; (v) stabilization of atherosclerotic plaques; (vi) 
anticoagulant effects; and (vii) inhibition of graft rejection after heart and kidney 
transplantation (Davignon and Laaksonen 1999). While the role of statin pleiotropic 
effects in cardiovascular prevention remains to be determined, statins have become 
one of the best-selling medication classes to date since their introduction into the 
marketplace in 1986, and include the following drugs commercially available in the US 
(in order of introduction): lovastatin, pravastatin, ﬂ  uvastatin, atorvastatin, simvastatin, 
and rosuvastatin.
Since the ﬁ  rst Adult Treatment Panel (ATP) recommendations in 1988 (Expert 
Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 
[Adult Treatment Panel II] 1993), published guidelines have focused on aggressive 
management of elevated low density lipoprotein cholesterol (LDL-C) in popula-
tions at risk for coronary heart disease (CHD). According to the National Choles-
terol Education Panel (NCEP) ATP III guidelines published in 2001, patients with 
established CHD, non-coronary atherosclerosis, diabetes mellitus, or greater than 
two major cardiac risk factors with a calculated Framingham risk score of greater 
than 20% are candidates for the most aggressive LDL-C goal of less than 100 mg/dL 
(Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in 
Adults [Adult Treatment Panel III] 2001). Subsequently, the Heart Protection Study Vascular Health and Risk Management 2008:4(2) 342
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(HPS) (Heart Protection Study Collaborative Group 2003) 
and Pravastatin or Atorvastatin Evaluation and Infection 
Therapy (PROVE-IT) (Cannon et al 2004) trial reported 
incremental 22% and 16% reductions in risk of CHD events 
with LDL-C levels lowered below 100 mg/dL in high-risk 
patients. As a result, major updates were proposed to the 
2001 guidelines. An ‘optional’ target of LDL-C less than 
70 mg/dL was recommended for patients at ‘very high risk’ 
of coronary events, which includes established CHD plus 
either non-coronary atherosclerosis, diabetes mellitus, or a 
greater than 20% calculated Framingham 10-year CHD risk. 
Furthermore, individuals with two or more risk factors and 
a calculated Framingham 10-year CHD risk of 10%–20% 
have the ‘optional’ target LDL-C of 100 mg/dL (Grundy 
et al 2004). While statins have become ﬁ  rst-line pharma-
cological therapy to attain the LDL-C goals laid out by the 
NCEP/ATP III guidelines, the clinical efﬁ  cacy of each drug 
varies signiﬁ  cantly (Table 1). This review summarizes the 
clinical efﬁ  cacy of the various statins with a particular focus 
on rosuvastatin.
First generation statins
Lovastatin, pravastatin, and ﬂ  uvastatin were introduced in 
the US in the late 1980s and 1990s; they represent the class 
members with the lowest potency. Typically, these statins 
need to be taken in doses of 40–80 mg daily to exceed a 30% 
reduction in LDL cholesterol levels (Jones et al 1998). Of 
the three, pravastatin has been most rigorously tested in 
controlled clinical trials and has demonstrated improved 
cardiovascular outcomes. Three trials – the West of Scotland 
Coronary Prevention Study (WOSCOPS), the Prospective 
Study of Pravastatin in the Elderly at Risk (PROSPER), 
and the Antihypertensive and Lipid-Lowering Treatment 
to Prevent Heart Attack Trial (ALLHAT-LLT) – evaluated 
the use of pravastatin at the dose of 40 mg daily vs no statin 
therapy in primary prevention patients (ie, those without 
known CHD). Two of the trials demonstrated reductions in 
LDL-C levels, cardiac mortality, and coronary events with 
pravastatin compared to placebo – WOSCOPS with 26%, 
28%, and 22% reductions, respectively, in men (Shepherd 
et al 1995); and PROSPER with 34%, 24%, and 19% 
reductions, respectively, in elderly patients (Shepherd et al 
2002). Although ALLHAT-LLT patients on pravastatin 
experienced an LDL-C reduction of 28%, the control group 
receiving usual care had a reduction of 11%, and no statisti-
cally signiﬁ  cant differences in coronary events or mortality 
were seen, perhaps due to the smaller difference in LDL-C 
levels. The relative lack of beneﬁ  t in ALLHAT led the NCEP 
ATP recommendation to lower LDL at least 30%–40% for 
CVD risk reduction (ALLHAT 2002).
Pravastatin has also proved to be effective in secondary 
prevention patients (ie, patients with a history of myocardial 
infarction (MI) or symptomatic coronary artery disease). 
In the Cholesterol And Recurrent Events (CARE) trial, 
patients receiving 40 mg of pravastatin daily enjoyed a 
24% reduction in coronary events and a non-signiﬁ  cant 
trend towards lower cardiac mortality compared to patients 
receiving placebo therapy (Sacks et al 1996). Similarly, in 
the Long-term Intervention with Pravastatin in Ischaemic 
Disease (LIPID) study, patients on 40 mg of pravastatin daily 
experienced a 24% reduction in coronary events, as well as 
a 24% reduction in cardiac mortality, compared to control 
patients (LIPID 1998).
There is less extensive data showing cardiovascular ben-
eﬁ  ts with lovastatin and ﬂ  uvastatin, although it is presumed 
that they improve outcomes similarly to pravastatin if titrated 
to equivalent lipid-lowering effects. Fluvastatin therapy 
reduces coronary events in special populations of second-
ary prevention patients including those who have already 
undergone percutaneous coronary intervention (Serruys 
et al 2002) and those who have received renal transplants 
(Holdaas et al 2003). Lovastatin, in contrast, has been 
assessed in a sizeable primary prevention population in the 
Air Force/Texas Coronary Atherosclerosis Prevention Study 
(AFCAPS/TexCAPS), in which men and women with aver-
age cholesterol levels receiving 20–40 mg of lovastatin daily 
saw a mean LDL-C reduction of 25% and a 37% reduction 
in ﬁ  rst coronary events (Downs et al 1998).
One particular advantage of pravastatin and ﬂ  uvastatin 
is their lower potential for drug – drug interactions, as they 
are not metabolized by the cytochrome P450 3A4 complex 
(CYP 3A4) as are many of the other statins; other medications 
Table 1 Lipid-lowering effects of the three generations of statins
Generation  Statins  Change in LDL  Change in HDL  Change in total   Change in triglycerides
       cholesterol
1st   Lovastatin, pravastatin, ﬂ  uvastatin  –21% to –42%  +2% to +12%  –16% to –34%  –6% to –27%
2nd  Simvastatin, atorvastatin  –26% to –60%  +5% to +16%  –19% to –45%  –12% to –53%
3rd  Rosuvastatin  –45% to –63%  +8% to +14%  –33% to –46%  –10% to –35%
Source: Adapted from, Vaughan CJ, Gotto AM Jr. 2004. Update on statins: 2003. Circulation, 110:886–92.Vascular Health and Risk Management 2008:4(2) 343
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and foods that modulate CYP 3A4 function will not affect 
the two statins’ activity. Whereas ﬂ  uvastatin is processed 
by another P450 complex, pravastatin does not undergo any 
processing by the cytochrome P450 system. As such, despite 
their lower potency they are attractive candidates for use in 
patients who have proven intolerant of more potent statins 
such as atorvastatin, simvastatin, or rosuvastatin.
Second generation statins
The second generation of statins, comprising atorvastatin 
and simvastatin, are currently the best-selling statins in the 
US. They have signiﬁ  cantly improved efﬁ  cacy in reducing 
LDL-C levels compared to the earlier statins. For example, to 
achieve greater than 30% reduction in LDL-C levels typically 
requires 20 mg daily of simvastatin and only 10 mg daily of 
atorvastatin (Jones et al 1998). A large body of data supports 
their use in both the primary and the secondary prevention 
populations. In the earliest trial, the Scandinavian Simvastatin 
Survival Study (4S), secondary prevention patients receiving 
20–40 mg of simvastatin experienced a 35% mean reduction 
of LDL-C levels, a 42% reduction in cardiac mortality, and 
a 34% reduction in coronary events compared to patients 
receiving placebo therapy (Scandinavian Simvastatin 
Survival Study Group 1994). The ﬁ  nding of beneﬁ  ts with 
simvastatin therapy was extended to primary prevention 
patients in the Heart Protection Study (HPS), a large trial with 
more than 20,000 patients that documented an 18% reduction 
in cardiac mortality and 26% reduction in coronary events 
with the use of 40 mg of simvastatin daily (Heart Protection 
Study Collaborative Group 2003).
The ﬁ  rst two prospective controlled trials to establish the 
efﬁ  cacy of atorvastatin in improving outcomes in primary 
prevention patients were the Anglo-Scandinavian Cardiac 
Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) and 
the Collaborative Atorvastatin Diabetes Study (CARDS). 
The studies demonstrated mean reductions with 10 mg 
of atorvastatin daily of 29% and 40% in LDL-C levels, 
respectively. ASCOT-LLA examined almost 20,000 patients 
with hypertension and found 29% less coronary events, albeit 
no signiﬁ  cant reductions of cardiac mortality, with atorvas-
tatin use (Sever et al 2003). CARDS focused on patient with 
non-insulin-dependent diabetes mellitus and demonstrated 
a 36% decrease in coronary events (Colhoun et al 2004). 
Of note, the ASPEN (Atorvastatin Study for Prevention of 
coronary heart disease Endpoints in Non-insulin-dependent 
diabetes mellitus) study showed that despite a 29% reduction 
in LDL-C levels (p  0.0001 compared to placebo), a statisti-
cally signiﬁ  cant reduction in the primary endpoint of major 
cardiovascular events (cardiovascular mortality, non-fatal 
major cardiovascular event or stroke, and unstable angina 
requiring hospitalization) was not observed with atorvas-
tatin compared to placebo (13.7% vs 15.0%, p-value = NS) 
(Arca 2007). Thus, atorvastatin and simvastatin offer similar 
beneﬁ  ts as the ﬁ  rst generation of statins when titrated for 
equivalent reductions in LDL-C levels.
The availability of the more potent second generation 
of statins compared to those of the ﬁ  rst generation in the 
drug class has offered the opportunity to study whether 
intensive statin therapy – intended to maximize LDL-C 
reduction – yields even better cardiovascular outcomes 
than a moderate level of statin therapy, for example those 
regimens commonly used in the 1990s and early 2000s. 
Most investigation comparing intensive vs moderate statin 
therapy has focused on secondary prevention patients, who 
have been considered most likely to beneﬁ  t from aggres-
sive lipid-lowering therapy. In the Treating to New Targets 
(TNT) study, patients with stable coronary artery disease 
who received 80 mg of atorvastatin daily experienced a 20% 
reduction in coronary events (but no reduction in mortality) 
compared to patients who received 10 mg of atorvastatin 
daily (LaRosa et al 2005). A similar trial, the Incremental 
Decrease in End Points Through Aggressive Lipid Lower-
ing (IDEAL) study, compared 80 mg of atorvastatin daily 
(intensive) and 20–40 mg of simvastatin daily (moderate) 
in patients with a history of MI, and although it did not ﬁ  nd 
a statistically signiﬁ  cant reduction in coronary events with 
intensive therapy, there was signiﬁ  cant reduction of second-
ary endpoints including coronary events plus stroke, as well 
as non-fatal MI (Pedersen et al 2005).
The data in support of intensive statin therapy is suggestive 
of beneﬁ  t in patients who have recently suffered coronary 
events. The Myocardial Ischemia Reduction with Aggressive 
Cholesterol Lowering (MIRACL) study established the util-
ity of high-dose atorvastatin therapy – 80 mg daily – started 
in patients after acute coronary syndromes. Patients receiv-
ing atorvastatin for 16 weeks experienced a 16% reduction 
in recurrent coronary events, although no signiﬁ  cant effect on 
mortality was observed (Schwartz et al 2001). The Pravastatin 
or Atorvastatin Evaluation and Infection Therapy – Throm-
bolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) 
study directly compared regimens comprising 80 mg of 
atorvastatin daily (intensive) vs 40 mg of pravastatin daily 
given after acute coronary syndromes (Cannon et al 2004). In 
those patients who had not previously been on statin therapy, 
there were reductions in LDL-C levels of 22% and 51% with 
pravastatin and atorvastatin, respectively. Comparing the two Vascular Health and Risk Management 2008:4(2) 344
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groups, there was a 16% reduction in the primary composite 
end point of CHD death, non-fatal MI, resuscitated sudden 
cardiac death, or emergency rehospitalization for recurrent 
ischemia observed in the intensive-therapy group relative to 
the moderate-therapy group after 2 years; event rates began to 
diverge as early as 3 months after the start of therapy (Cannon 
et al 2004). This important ﬁ  nding highlights the need to treat 
very-high-risk patients to lower LDL-C goals (70 mg/dL) 
than had previously been recommended (100 mg/dL) 
(Grundy et al 2004).
In March 2007, atorvastatin was approved as the ﬁ  rst 
cholesterol-lowering drug to reduce the risk of hospitalization 
for heart failure. The decision was based on a sub-analysis 
of the TNT study, which showed a statistically signiﬁ  cant 
reduction in heart failure hospitalization in patients with a 
prior history of heart failure receiving either 80 mg (10.6%) 
or 10 mg (17.3%; HR: 0.59, 95% CI, p = 0.008) of atorv-
astatin. These ﬁ  ndings suggest potential beneﬁ  t of statins at 
the level of cardiac myocytes and peripheral vasculature. In 
this study, for each 1 mg/dL reduction in LDL-C, the risk 
of heart failure admission decreased by 0.6% (p = 0.007) 
(Khush et al 2007).
Third generation statin
Finally, there is a single commercially available drug in 
the third, high-potency generation of statins, rosuvastatin. 
Three unique chemical characteristics of rosuvastatin 
provide enhanced potency against HMG-CoA reductase. 
First, in addition to the dihydroxyheptenoic acid side chain 
common to all statins, rosuvastatin has a ﬂ  uorinated phenyl 
group and a polar methane sulphonamide group provid-
ing multiple sites of activity against HMG-CoA reductase 
(Istvan and Desienhofer 2001). Second, atorvastatin and 
rosuvastatin have enhanced binding enthalpies for HMG-
CoA reductase. Binding enthalpy refers to the strength of 
the interaction between the inhibitor and target enzyme. 
These two statins are the only members of their class to 
form a hydrogen bond with the hydroxyl group of Ser565 
on HMG-CoA reductase. A shorter hydrogen bond length 
and involvement of sulfonyl groups contribute to superior 
enzyme inhibition by rosuvastatin (Carbonell and Freire 
2005). Third, the hydrophilic nature of rosuvastatin may also 
reduce the number of drug-drug interactions by eliminat-
ing dependence on metabolic conversion to a water-soluble 
molecule (Holdgate et al 2003).
Rosuvastatin’s clinical efﬁ  cacy has been extensively 
studied in over 20,000 patients with renal dysfunction (53%), 
hypertension (52%), cardiovascular disease (36%), diabetes 
mellitus (17%), and age greater than 65 years (31%) (Brewer 
2003). In a multicenter, double-blind, placebo-controlled 
trial, 10 mg rosuvastatin produced reductions in total 
cholesterol (TC) (35%), LDL-C (50%), non-HDL-C/HDL-C 
(50%), Apo-B (40%), and triglyceride (TG) (19%) with 
an increase in HDL-C (8%) within 12 weeks of initiating 
therapy (Olsson et al 2002). In another study of 129 patients 
receiving rosuvastatin (10–40 mg), LDL-C was reduced by 
47%–57% at 6 weeks vs 38%–54% in patients treated with 
atorvastatin (10–80 mg) (Schneck et al 2003). The maximum 
recommended dose of rosuvastatin is 40 mg daily. In an effort 
to investigate the impact of rosuvastatin on cardiovascular 
risk reduction, AstraZeneca has embarked on a comprehen-
sive, global program known as GALAXY. The GALAXY 
program focuses on: 1) atherogenic lipid proﬁ  les, 2) changes 
in atheroma volume, and 3) cardiovascular morbidity and 
mortality. A number of additional studies focus on special-
ized populations including diabetics, and ethnic minorities 
(Schuster 2007).
One of the ﬁ  rst studies establishing clinical efﬁ  cacy 
and superiority of rosuvastatin over other commonly 
used statin agents was The Statin Therapies for Elevated 
Lipid Levels Compared Across Doses to Rosuvastatin 
(STELLAR) study (Jones et al 2003). A 6-week, parallel-
group, open-label, randomized, multi-center trial in over 
2400 patients with hypercholesterolemia, STELLAR com-
pared rosuvastatin (10–40 mg) with atorvastatin (10–80 mg), 
simvastatin (10–80 mg), and pravastatin (10–40 mg) across 
clinically applicable dose ranges. Rosuvastatin (n = 473) 
reduced LDL-C by 46%–55% vs 37%–51% with atorvas-
tatin (n = 641), 28%–46% with simvastatin (n = 648), and 
20%–30% with pravastatin (n = 485). Across the range of 
doses, rosuvastatin reduced LDL-C by a mean of 8.2% more 
than atorvastatin, 26% more than pravastatin, and 12%–18% 
more than simvastatin (p  0.001). Milligram-equivalent 
LDL-C reduction was greater with rosuvastatin than all other 
statins (p  0.002). Rosuvastatin also reduced TC more sig-
niﬁ  cantly than all other statins (p  0.001) and decreased TG 
more signiﬁ  cantly (p  0.001) than simvastatin and pravas-
tatin. Similarly, rosuvastatin increased HDL-C by a mean of 
7.7%–9.6% compared to 2.1%–6.8% in all other groups.
Two studies have evaluated efﬁ  cacy of rosuvastatin 
therapy at 52 weeks. In the ﬁ  rst randomized, double-blind, 
multi-center study, 412 patients with LDL-C ranging between 
160–250 mg/dL received ﬁ  xed doses of rosuvastatin (5 mg, 
n = 138 or 10 mg, n = 134) or atorvastatin (10 mg, n = 140) 
for 12 weeks followed by dose adjustments up to 80 mg 
if NCEP/ATP II LDL-C goals were not met. Both doses Vascular Health and Risk Management 2008:4(2) 345
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of rosuvastatin resulted in greater LDL-C reductions than 
atorvastatin at 12 weeks (46% and 50% respectively vs 39%, 
p  0.001 for both groups) and 52 weeks (47% and 53% 
respectively vs 44%, p  0.05 and p  0.001). Ninety-eight 
percent of patients treated with rosuvastatin (10 mg initial 
dose) achieved NCEP/ATP-II LDL-C goals compared to 
87% with atorvastatin. Notably, 82% of patients treated with 
10 mg rosuvastatin did not require dose titration to achieve 
goal LDL-C levels as compared to 59% of patients receiving 
atorvastatin (10 mg) (Olsson et al 2002).
In a similarly designed trial, 477 hypercholesterolemic 
patients received ﬁ  xed doses of rosuvastatin (5 mg or 10 mg), 
pravastatin (20 mg), or simvastatin (20 mg) for 12 weeks 
followed by 40 weeks of liberal dose titration up to 80 mg 
for rosuvastatin and simvastatin and 40 mg for pravastatin. 
At 12 weeks both doses of rosuvastatin had reduced LDL-C 
levels (39% and 47%, respectively) more signiﬁ  cantly than 
pravastatin (26.5%) and simvastatin (34.6%) (p  0.05). 
After 52 weeks, more rosuvastatin-treated patients achieved 
their ATP II LDL-C goals (88% and 87.5%, respectively) 
than recipients of pravastatin (60%) or simvastatin (72.5%) 
(Brown et al 2002).
A unique aspect of the GALAXY program is the scale 
and breadth of subpopulations studied. Speciﬁ  c focus groups 
include: Type II diabetics (Tuomilehto et al 2004), hemodi-
alysis recipients, patients with congestive heart failure (Krum 
et al 2006; Raina et al 2006) and speciﬁ  c ethnic groups. 
Three prospective studies evaluating rosuvastatin efﬁ  cacy in 
under-represented populations have recently been presented, 
namely (African American Rosuvastatin Investigation of 
Efﬁ  cacy and Safety) (Ferdinand et al 2006), STARSHIP 
(STudy Assessing RoSuvastatin in HIspanic Population) 
(Llorett et al 2006), and IRIS (Investigation of Rosuvastatin 
In South Asian Subjects) (Deedwania et al 2006).
The recently published CORONA (Controlled Rosuvas-
tatin Multinational Trial in Heart Failure) compared clinical 
outcomes for rosuvastatin 10 mg daily vs placebo speciﬁ  -
cally in 5011 patients with systolic heart failure of ischemic 
origin aged 60 years or over with New York Heart Associa-
tion (NYHA) functional class II or III/IV, and had received 
optimal medical therapy. After 33 months of follow-up 
(median), only a small difference in the primary composite 
endpoint of cardiovascular death, non-fatal MI, or non-fatal 
stroke between the rosuvastatin and placebo treatment groups 
(27.5% vs 29.3%, p = NS). A post-hoc analysis showed a 
lower rate of non-fatal or fatal MI or stroke in patients receiv-
ing rosuvastatin compared with placebo (9.0% vs 10.6%, 
HR = 0.84; p = 0.05).
Changes in atheroma volume
The established benefit of statin therapy has limited 
clinical trial design due to concerns over the ethics of 
placebo-controlled randomization in moderate to high-risk 
populations. These ﬁ  ndings have spurred interest in evaluat-
ing the direct effects of lipid-modifying therapy on athero-
matous plaque burden using surrogate measures of clinical 
outcomes such as carotid intima-media thickness (CIMT) and 
coronary plaque volume. Studies such as the Atherosclerosis 
Progression in Familial Hypercholesterolemia (ASAP) trial 
and Arterial Biology for the Investigation of the Treatment 
Effects of Reducing Cholesterol (ARBITER) trial demon-
strate the ability of B-mode ultrasound to non-invasively 
quantitate changes in carotid plaque with statin therapy. The 
ASAP trial demonstrated plaque regression from baseline in 
hypercholesterolemic patients treated with atorvastatin 80 mg 
compared to simvastatin 40 mg (–0.031 mm vs 0.036 mm, 
p  0.0005 and p  0.0017, respectively) (Smilde et al 
2001). The ARBITER study similarly showed a reduction 
in CIMT by 0.034 mm with atorvastatin 80 mg vs 0.025 mm 
with pravastatin 40 mg after 12 months (p = 0.03) (Taylor 
et al 2002). The effect of rosuvastatin on CIMT will be 
prospectively evaluated in the Measuring Effects on intima 
media Thickness: an Evaluation Of Rosuvastatin (METEOR) 
study. Low risk subjects (n = 840) with signs of sub-clinical 
atherosclerosis will be randomized (5:2) in this parallel-
group study to rosuvastatin (40 mg) or placebo for 104 
weeks. The primary endpoint will be the change in CIMT 
from baseline. Secondary endpoints include the effect of 
rosuvastatin on lipid proﬁ  les and C-reactive protein levels 
(Crouse et al 2004).
The Outcome of Rosuvastatin treatment on carotid 
artery atheroma: a magnetic resonance Imaging Observa-
tioN (ORION) study was a randomized, double-blind trial to 
assess the effect of rosuvastatin on carotid artery atheroma 
in asymptomatic patients with hypercholesterolemia. Thirty-
ﬁ  ve patients with LDL-C between 100–250 mg/dL and 
16%–79% reduction of the carotid artery diameter assessed 
by ultrasound or MRI received rosuvastatin 5 mg (n = 15) or 
40 mg (n = 20) daily. Of note, 14 patients in the high-dose 
rosuvastatin group were up-titrated to 80 mg daily then back 
titrated to 40 mg daily (80 mg exposure range, 70–701 days). 
LDL-C was reduced from baseline by 39% and 58% in the 
low- and high-dose groups, respectively (p  0.001). There 
was no signiﬁ  cant difference in the changes of the carotid 
artery wall volume between the groups. In plaques with a 
lipid-rich core, high-dose rosuvastatin reduced the percent-
age of lipid-rich necrotic core at the most diseased section by Vascular Health and Risk Management 2008:4(2) 346
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35.5% (p = 0.006) with 90% of plaques showing regression 
from baseline (Hatsukami et al 2005).
Recently, the Measuring Effects on Intima-Media Thick-
ness: an Evaluation of Rosuvastatin (METEOR) was pub-
lished. In this randomized, double-blind, placebo-controlled 
study of 948 individuals with minimal coronary risk factors, 
patients received either rosuvastatin (40 mg daily) or placebo. 
At 2 years follow up, the change in maximum CIMT for the 
12 carotid sites was –0.0014 (95% CI, –0.0041 to 0.0014) 
mm/year for the rosuvastatin group vs 0.0131 (95% CI, 
0.0087–0.0174) mm/year for the placebo group (p  0.001). 
The change in mean CIMT for the rosuvastatin group for the 
common carotid artery sites was 0.0004 (95% CI, –0.0011 
to 0.0019) mm/year (p  0.001). Taken together, these data 
suggest that rosuvastatin may reduce progression of athero-
sclerotic disease, yet fails to induce signiﬁ  cant regression 
(Crouse 2007).
While CIMT provides a surrogate marker of coronary 
atherosclerosis, volumetric intravascular ultrasound (IVUS) 
has emerged as a direct measure of changes in coronary 
plaque burden. Using a 30–40 MHz transducer attached to 
a catheter, axial resolution of 80–100 microns and lateral 
resolution of 200–250 microns can be achieved. IVUS was 
used to evaluate clinical atheromatous progression in the 
Reversing Atherosclerosis with Aggressive Lipid Lower-
ing (REVERSAL) trial, which compared treatment with 40 
mg pravastatin vs 80 mg atorvastatin in 2163 patients with 
a mean baseline serum LDL-C level of 150 mg/dL (Nissen 
et al 2004). Pravastatin reduced serum LDL levels to 110 
mg/dL, while intensive therapy with atorvastatin reduced 
LDL-C levels to 79 mg/dL. Notably, levels of high-sensitivity 
C-reactive protein (hs-CRP) were signiﬁ  cantly reduced by 
5.2% with pravastatin therapy vs 36.4% with atorvastatin 
therapy. IVUS examination at baseline and at 18 months 
follow up was performed to evaluate for percent change in 
atheroma volume. In the pravastatin cohort, 2.7% progression 
of atheroma volume was observed vs no signiﬁ  cant change in 
the atorvastatin arm (–0.4%). The REVERSAL trial marked 
the advent of IVUS examination as an effective marker of 
plaque regression in response to lipid-lowering therapy.
Recently, A Study To Evaluate the Effect of Rosuvastatin 
On Intravascular Ultrasound-Derived Coronary Atheroma 
Burden (ASTEROID) demonstrated signiﬁ  cant reductions 
in mean LDL-C (130.4 ± 34.3 mg/dL to 60.8 ± 20.0 mg/dL, 
p  0.001) and increases in mean HDL-C from baseline (43.1 ± 
11.1 mg/dL to 49.0 ± 12.6 mg/dL, p  0.001) in 349 patients 
with angiographic evidence of coronary atherosclerosis receiv-
ing 40 mg of rosuvastatin daily for 24 months (Nissen et al 
2006). IVUS assessment showed reductions in median percent 
atheroma volume (PAV) from baseline (–0.79%; 97.5% CI, 
–1.21% to –0.53%, p  0.001) and median total atheroma 
volume of –12.5 mm3 from baseline (95% CI, –15.1 to –10.5 
mm3, p  0.001). In this prospective, open-label, multi-center, 
blind endpoints trial PAV was calculated as the percent change 
in luminal cross-sectional area subtracted from the external 
elastic membrane cross-sectional area.
While promising, the results of this study were tempered 
by: 1) the lack of a control group receiving a somewhat less 
intensive LDL-C lowering regimen, 2) the absence of paired 
IVUS measurements in less diseased coronary segments 
demonstrating reproducibility of atheroma volume measure-
ments, and 3) exclusion of patients with coronary stenoses 
measuring 50% throughout a target segment (Blumenthal 
et al 2006). The clinical correlate to changes in atheroma 
burden identiﬁ  ed by ASTEROID will be evaluated in the 
outcomes component of GALAXY via studies such as the 
Justiﬁ  cation for the Use of Statins in Primary Prevention: 
An Intervention Trial Evaluating Rosuvastatin (JUPITER) 
study (Ridker et al 2003).
Managing statins in clinical practice
Since 2004, published guidelines have emphasized the need for 
aggressive LDL-C reduction, resulting in a trend towards more 
frequent and higher doses of statin therapy in patients. In the 
era of ‘lower is better’, the safety of aggressive statin therapy 
and the effects of lower LDL-C reductions have been raised. 
Numerous studies support the concept that statin therapy is 
not merely safe, but beneﬁ  cial. A meta-anlaysis performed 
by the Cholesterol Treatment Trialists’ (CTT) Collaborators 
in 2005 evaluated over 90,000 participants in 14 statin trials 
and demonstrated no signiﬁ  cant differences in the rates of 
death from non-vascular causes in statin treatment groups 
compared with placebo (3.8% statin treated vs 4.0 placebo 
control, p = 0.1) (Baigent et al 2005). Focusing on 27,000 
patients from 5 trials using ‘intensive statin therapy’, no evi-
dence of any serious adverse effect was associated with low 
LDL-C levels (Armitage 2007). A recent analysis of the TNT 
study evaluated the incidence of treatment-associated adverse 
event rates across quintiles of LDL-C reduction (LaRosa et al 
2007). No signiﬁ  cant difference in the incidence of treatment 
associated muscle side effects, changes in liver enzymes, 
cancer death, hemorrhagic stroke, or suicide were observed 
across quintiles.
In a recent study, Alsheikh-Ali and colleagues investi-
gated the relationship between low LDL-C levels achieved 
by statin therapy and adverse effects such as elevated liver Vascular Health and Risk Management 2008:4(2) 347
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enzymes, rhabdomyolysis, and cancer (Alsheikh-Ali et al 
2007). In this meta-analysis of 23 statin trials with over 
309,000 person-years, no signiﬁ  cant relationship between 
percent LDL-C lowering and elevated liver enzymes 
(R2  0.001, p = 0.91), rhabdomyolysis (R2 = 0.05, p = 0.16), 
or rates of cancer (R2 = 0.09, p = 0.92) were observed. 
Signiﬁ  cantly higher rate of elevated liver enzymes were 
noted in the high-dose statin recipients compared with 
the intermediate or low-dose statins treatment groups 
(p  0.001 for all pair-wise comparisons). The dose-effect 
was independent of the particular statin used. For each 10% 
reduction in LDL-C the rate of elevated liver enzymes 
was 2.5 times higher with 80 mg of lovastatin, 1.6 times 
higher with 80 mg of simvastatin, and 4.0 times higher 
with 80 mg of atorvastatin as compared to their respective 
low-dose counterparts. Taken together, these data suggest 
the degree of LDL-C lowering does not correlate with 
adverse events; rather the dose of statin used may be more 
relevant. The National Lipid Association (NLA) Statin 
Safety Task Force (McKenney et al 2006) has published 
guidelines regarding the management of statin-associated 
adverse effects (Table 2).
Muscle toxicity
Myopathy is deﬁ  ned by any muscular discomfort such as 
pain, soreness, weakness, or cramping accompanied by an 
increase in creatine kinase (CK) levels greater than ten times 
the upper limit of normal. The National Lipid Association 
Muscle Expert Panel recenty deﬁ  ned ‘clinically important 
rhabdomyolysis as any evidence of muscle cell destruction 
or enzyme leakage, regardless of the CK level when mea-
sured, considered to be causally related to a change in renal 
function’. The panel suggested the term rhabdomyolysis be 
replaced by classes of absolute CK elevation with mild CK 
increases being less than 10 times the upper limit of normal 
(ULN), moderate increases being greater than or equal 
to 10 times the ULN, and marked increases being greater 
than or equal to 50 times the ULN (Thompson et al 2006). 
Table 2 Summary of National Lipid Association Statin Safety Recommendations
Muscle effects
 1.    Pretreatment measurement of CK levels is generally not necessary unless an individual is at high risk.a
 2.    Routine measurements of CK levels are unnecessary in asymptomatic patients.
 3.    Counsel patients on the possiblity of muscle discomfort while on statin therapy and the importance of reporting symptoms.
 4.    In symptomatic patients, CK levels should be measured.
   a.    If CK levels  10 times the ULN then statin therapy may be continued or doses reduced with close monitoring 
of symptoms.
   b.    If CK levels  10,000 IU/L or above 10 times the ULN, then admit for IV hydration therapy, monitoring of renal 
function, and treatment of rhabdomyolysis.
   c.    Irrespective of CK levels, if muscle symptoms are intolerable, statin therapy should be discontinued with possible 
reinstitution of a different agent or lower dose once asymptomatic.
   d.    If symptoms recur, alternative therapies should be considered.
Hepatic effects
 1.    Measure transaminase levels before initiating therapy, 12 weeks after starting therapy, after a dose adjustment, and periodi-
cally thereafter.
 2.    Monitor for signs of potential hepatotoxicity such as jaundice, malaise, fatigue, and lethargy. If present, measure transaminase 
levels, fractionated bilirubin levels, and liver function tests.
 3.    If asymptomatic transaminase levels are between 1 to 3 times the ULN, then consider continuing statin therapy with close 
follow up testing.
 4.    If transaminase levels increase  3 times the ULN, then reduce the statin dose or discontinue treatment while ruling out 
other possible etiologies.
 5.    If objective evidence of liver injury is documented, then discontinue the statin and refer the patient to a gastroenterologist.
Renal effects
 1.    Routine measurements of serum creatinine and proetinuria are not necessary for patients on statins.
 2.    Pre-treatment baseline creatinine levels may be helpful in identifying patients with underlying renal disease who may be at 
risk for higher muscle toxicity.
 3.    If creatinine levels increase while on statin therapy, an adjustment in statin dosing may be required.
 4.    If proteinuria is detected, consider adjusting the statin dose.
 5.    Any perturbation of renal indices should warrant further investigation of other non-statin related causes.
 6.    In patients with chronic kidney disease, statin therapy may be intiated with close attention to dose adjustments in moderate 
to severe renal disease.
Notes: aRisk factors for muscle toxicity include: concomitant therapy with ﬁ  bric acid derivatives, erythromycin, or azole antifungals, advanced age, small body habitus, worsening 
renal function, ongoing infection, trauma such as recent surgery, alcohol abuse, and untreated hypothyroidism.
Abbreviations: CK, creatine kinase; ULN, upper limit of normal.Vascular Health and Risk Management 2008:4(2) 348
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The most common side effect of statins remains myalgia 
without changes in CK levels (Bays 2006). In clinical trials, 
the rates of reported myalgias range between 1.5% and 3.0%. 
In clinical practice, the incidence of myalgias is between 0.3% 
and 33%, suggesting that selection critera for clinical trials may 
exclude patients susceptible to statin-induced myalgias.
Law and colleagues reviewed 21 statin-based clinical 
trials with over 180,000 person years for evidence of muscle 
toxicity. The incidence of myopathy in this study was 11 per 
100,000 person-years. The incidence of rhabdomyolysis in 2 
cohort studies was 3.4 (1.6–6.5) per 100,000 person-years 
and 10-fold higher when gemﬁ  brozil was used in combina-
tion with statins. For statins metabolized by cytochrome P450 
3A4 (CYP3A4), such as lovastatin, atorvastatin, and simv-
astatin), the incidence was 4.2 per 100,000 person-years. In 
this group, interaction with drugs known to inhibit CYP3A4 
(ie, erythromycin and azole antifungals) occurred in 60% of 
case (Law and Rudnicka 2006). These ﬁ  ndings are supported 
by reports from the FDA AER’s database of 0.3–2.2 cases of 
myopathy and 0.3–13.5 cases of rhabdomyolysis per million 
statin prescriptions (McKenney et al 2006).
The risk of myopathy can be associated with all statins 
(Davidson et al 2006). In 3 large trials using pravastatin 
40 mg daily compared to placebo, there were no reported 
cases of myopathy. In two trials of atorvastatin (10 mg 
daily) vs placebo, three cases of mypathy were documented 
(ASCOT-LLA and CARDS). The incidence of myopathy 
was 0.01% per year in several studies using simvastatin 
(20–40 mg daily). No cases of myopathy were reported in 
patients receiving ﬂ  uvastatin (40 mg twice daily) compared 
to placebo (Armitage 2007). In a separate study, one patient 
with renal transplantation and severe trauma experienced 
rhabdomyolysis (Serruys et al 2002). Lovastatin (40–80 mg 
daily) is rarely associated with myopathy. Six documented 
cases were reported in a large trial of 8000 individuals 
(Bradford et al 1994). In general all statins can cause myopa-
thy with a risk of progressing to rhabdomyolysis. The risk 
appears to increase with higher doses.
Risk factors for the development of statin-induced myopa-
thy include drug-drug interactions (ie, ﬁ  bric acid derivatives, 
erythromycin, and azole antifungals), advaced age, small 
body habitus, worsening renal function, ongoing infection, 
trauma such as recent surgery, alcohol abuse, and untreated 
hypothyroidism. Current guidelines recommend ruling out 
these possible etiologies whenever patients present with 
muscle symptoms or an increased CK level while on statin 
therapy. Pretreatment measurement of CK levels is generally 
not necessary unless an individual is at high risk of developing 
myopathy with statin therapy. Routine measurements of CK 
levels are also unnecessary in asymptomatic patients. Coun-
seling patients on the possiblity of muscle discomfort while 
on statin therapy and the need to report these complaints 
to their primary physicians is of paramount importance. In 
symptomatic patients, CK levels should be measured. If CK 
levels are less than 10 times the ULN then statin therapy 
may be continued or doses reduced with close monitoring of 
symptoms. If CK levels are greater than 10,000 IU/L or above 
10 times the ULN, then patients should be admitted for IV 
hydration therapy, monitoring of renal function, and treatment 
of rhabdomyolysis. Irrespective of CK levels, if muscle symp-
toms are intolerable, statin therapy should be discontinued 
with possible reinstitution of a different agent or lower dose 
once asymptomatic. If symptoms recur, alternative therapies 
should be considered (McKenney et al 2006).
Hepatic effects of statin therapy
Abnormal hepatic transaminase levels (LFT) are recognized 
as an infrequent occurrence of statin therapy. In particular, 
the transaminases (alanine and aspartate) seem to increase 
within the ﬁ  rst 6 months of therapy. In the majority of clini-
cal trials, elevated alanine aminotransferase (ALT) levels 
greater than three times the upper limit of normal on 2 or 
more measurements have been considered a safety endpoint. 
Elevated ALT levels occur in 1% of patients receiving 
low to intermediate dose statins and in 2%–3% of patients 
on high dose therapy (80 mg daily) (Cohen et al 2006). In 
70% of cases, transaminase elevations resolve spontaneously 
even if statin therapy is continued (Bays 2006). According 
to the NLA Statin Safety Task Force, the incidence of liver 
function abnormalities was more common in obese patients, 
diabetics, older individuals, and those receiving multiple 
medications. The cause of elevated transaminases remains 
unknown and does not appear to be related to the degree of 
LDL-C reduction (McKenney et al 2006).
Current guidelines recommend measuring transaminase 
levels before initiating therapy, 12 weeks after starting 
therapy, after a dose adjustment, and periodically thereafter. 
Signs of potential hepatotoxicity such as jaundice, malaise, 
fatigue, and lethargy should alert physicians to measure 
transaminase levels and liver function tests. Fractionated 
bilirubin levels are recommended to rule out hepatic injury. 
If isolated asymptomatic transaminase levels are increased 
between one to three times the ULN, then follow up testing 
should be performed and the statin may be continued. If 
transaminase levels increase about three times the ULN, then 
the test ought to be repeated and other etiologies ruled out. Vascular Health and Risk Management 2008:4(2) 349
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The physician should consider reducing the dose of statin or 
discontinuing the medication based on clinical judgement. If 
objective evidence of liver injury is documented, then discon-
tinue the statin and refer the patient to a gastroenterologist 
(Cohen et al 2006; McKenney et al 2006).
Renal effects of statin therapy
According to a recent report by the NLA Statin Safety Task 
Force, statins do not appear to be associated with renal 
failure or insufﬁ  ciency without concomitant rhabdomyoly-
sis (Kasiske et al 2006). The FDA AERS database reports 
0.3–0.9 cases per one million statin prescriptions (Davidson 
et al 2006). In general, routine measurements of serum 
creatinine and proetinuria are not necessary for patients on 
statins. Pre-treatment baseline creatinine levels may be help-
ful in identifying patients with underlying renal disease who 
may be at risk for higher muscle toxicity on statin therapy. If 
creatinine levels are noted to increase while on statin therapy, 
an adjustment in statin dosing may be required. Discon-
tinuation of the drug is generally not necessary. Similarly, 
if proteinuria is detected, discontinuing statin therapy is not 
necessary, while dose adjustments may be reasonable. Any 
perturbation of renal indices should warrant further inves-
tigation of other non-statin related causes. In patients with 
chronic kidney disease, statin therapy may be initiated with 
close attention to dose adjustments in moderate to severe 
renal disease (McKenney et al 2006).
Safety proﬁ  le of rosuvastatin
The safety of rosuvastatin has been extensively evaluated in 
the largest pre-marketing clinical development program for 
any statin currently in use. Over 12,500 patients received 
rosuvastatin 5–80 mg in 27 controlled clinical trials over 6–96 
weeks. Over 5000 patients received the highest marketed dose 
(40 mg) (Food and Drug Administration 2006). In this analy-
sis, rates of pharyngitis, headache, diarrhea, dyspepsia, nau-
sea, myalgia, and withdrawal rates due to adverse effects were 
similar to currently marketed statins. Myopathy as deﬁ  ned 
by creatine kinase (CK) elevation greater than three times 
the upper limit of normal (ULN) occurred in 0.1%–0.4% 
of patients receiving 5–40 mg rosuvastatin with an overall 
rate of 0.2% for all doses. No cases of rhabdomyolysis were 
reported (McAfee et al 2006).
Hepatotoxicity as deﬁ  ned as increased alanine trans-
aminase (ALT) by three times the ULN were reported in 
0.5%, 0.1%, 0.1%, and 0.3% of patients receiving 5, 10, 
20, and 40 mg of rosuvastatin (McAfee et al 2006). Similar 
results (0.2%) have been reported across the dose ranges 
of atorvastatin, simvastatin, and pravastatin (Schneck et al 
2003; Grundy 2005). As a result, serum transaminases should 
be monitored prior to initiation of statin therapy, 12 weeks 
following initiation and every 6 months thereafter
Dipstick-positive proteinuria was reported in 0.2%, 0.6%, 
and 0.7% of patients receiving 5, 10, or 20 mg of rosuvas-
tatin compared to 0.6% receiving placebo. The incidence of 
proteinuria was similar to reported rates with atorvastatin, 
simvastatin, and pravastatin across dose ranges. Urinary 
protein was predominantly of low molecular weight by 
gel electrophoresis, suggesting decreased reabsorption vs 
increased glomerular leakage as the primary cause. Reported 
proteinuria was transient, reversible, and not associated with 
a reduction in glomerular ﬁ  ltration rate (GFR) in long-term 
follow up (McAfee et al 2006). In 2005, a critical analysis 
of 38 reports of renal insufﬁ  ciency in patients treated with 
rosuvastain, led the FDA to conclude that ‘no consistent 
pattern of clinical presentation or of renal injury is evident 
among the cases of renal failure reported to date that clearly 
indicate causation by [rosuvastatin]’ (Zipes et al 2006).
A recent analysis of the Rosuvastatin Clinical Develop-
ment Program reviewed 3956 patients treated with short-term 
(6–8 weeks) of rosuvastatin (5–40 mg) to determine the 
effect of rosuvastatin treatment on the estimated glomerular 
ﬁ  ltration rate (eGFR). For each dose of rosuvastatin, eGFR 
signiﬁ  cantly increased individually and for all doses com-
bined vs baseline (range +0.9 to +3.2 mL/min/1.73 m2). 
In 525 patients from placebo-controlled trials rosuvas-
tatin increased eGFR by +0.8 mL/min/1.73 m2 (95% CI 
+0.1 to +1.5) compared to baseline (p  0.04) and placebo-
treated patients (95% CI –2.5 to –0.5, p  0.001) (Vidt et al 
2006). These data suggest a potential beneﬁ  cial effect of 
‘short-term’ rosuvastatin on renal function.
Since FDA approval in 2003, few studies have evaluated 
the safety of rosuvastatin in actual clinical practice. A Dutch 
historical cohort study in over 45,000 patients compared the 
incidence of adverse event reports (AER: myopathy, rhab-
domyolysis, acute renal failure, and hepatic impairment) in 
those receiving rosuvastatin (n = 10,147) with those receiv-
ing other statins (n = 37,396) and statin-naïve (n = 99,935) 
individuals from 2003 to 2004. In this analysis, the incidence 
of AER was lower than 1 in 3000 person-years’ exposure to 
statins, with no signiﬁ  cant difference between recipients of 
rosuvastatin compared to other statins. The incidence per 
1000 person-years for patients treated with rosuvastatin 
was 0.00, 0.00, 0.31, 0.00, and 5.34 for myopathy, rhabdo-
myolysis, acute renal failure, hepatic impairment, and all-
cause mortality, respectively. In the ‘other-statins’ cohort, Vascular Health and Risk Management 2008:4(2) 350
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the incidence per 1000 person-years was 0.03, 0.00, 0.20, 
0.11, and 11.48 for myopathy, rhabdomyolysis, renal failure, 
hepatic impairment, and all-cause mortality, respectively 
(Goettsch et al 2006).
An American post-marketing analysis from August 2003 
through October 2004 reported 26 cases of myopathy and 
rhabdomyolysis yielding a 1-year myopathy/rhabdomyolysis 
incidence of 0.43 per 100,000 rosuvastatin prescriptions 
(Zipes et al 2006). Another post-marketing analysis compared 
AERs for rosuvastatin vs simvastatin, pravastatin, and ator-
vastatin between October 2003 and September 2004. In the 
concurrent time period, the composite rate of rhabdomyolysis, 
proteinuria/nephropathy, or renal failure was higher in those 
treated with rosuvastatin compared to all other statins ana-
lyzed (p  0.001 per group) (Al-sheikh-Ali et al 2005).
Real-world effectiveness: 
implications for patient 
management
Substantial evidence suggests that dyslipidemia is under-
treated in real-world clinical practice. Before publication 
of the NCEP-ATPIII guidelines in 2001, an analysis of 
4888 patients with dyslipidemia from 5 regions across the 
United States revealed that only 38% achieved speciﬁ  ed 
NCEP LDL-C targets. Especially concerning was the ﬁ  nding 
that among patients with established CHD, only 18% achieved 
LDL-C targets (Pearson et al 2000). In 2005, a national survey 
of 4885 patients demonstrated some improvement in attain-
ment of LDL-C goals, however patients with diabetes (55%) 
and other CHD risk equivalents (40%) were less likely to 
have achieved their LDL cholesterol targets than those with 
CHD (62%) (Davidson et al 2005). Suggested mechanisms for 
poor results in real-world practice include: failure to identify 
candidates for pharmacologic therapy, failure to appropriately 
titrate drug therapy, poor patient adherence and follow-up, 
and cost-related issues (Davidson 2006).
Few studies focus on the effectiveness of statin-based 
treatment for dyslipidemia. An analysis of 8251 patients in a 
managed care database receiving treatment with rosuvastatin, 
atorvastatin, simvastatin, pravastatin, lovastatin, and ﬂ  uvas-
tatin between 2003 and 2004 demonstrated greater absolute 
and percent reductions in LDL-C, TG, and TC levels with 
rosuvastatin than with other statins (all p  0.05 except for 
TG reduction vs atorvastatin). In this study, NCEP-ATP III 
goal attainment was higher with rosuvastatin than with other 
statins after adjustment for age, sex, baseline LDL, risk status, 
dose, and duration of therapy (p  0.05) (Bullano et al 2006). 
Another study evaluated 775 high-risk patients (deﬁ  ned as 
having CHD or CHD risk-equivalents) from 500 physician 
ofﬁ  ces in the mid-western US receiving statin treatment. In 
this analysis, percent LDL-C reduction was signiﬁ  cantly 
greater with rosuvastatin vs atorvastatin or simvastatin (37% 
vs 28% or 27%, respectively, p  0.05). The estimated 
percentage of patients achieving target goals set for by the 
NCEP-ATPIII was signiﬁ  cantly higher (p  0.05) with 
rosuvastatin (69.7%) compared with atorvastatin (54.8%) or 
simvastatin (51.2%) after adjusting for baseline characteris-
tics (Ohsfeldt et al 2006).
For those patients in whom statin monotherapy is 
insufﬁ  cient to reach the desired LDL-C goal as laid out 
by the NCEP ATP III guidelines, an attractive adjunctive 
pharmacological option has emerged with the introduction 
of ezetimibe, the ﬁ  rst of a novel class of cholesterol drugs 
that works by inhibiting uptake of cholesterol in the small 
intestine. It therefore exploits a different mechanism than 
the statin drugs, with the potential for synergy between the 
two classes. The addition of ezetimibe to atorvastatin or to 
simvastatin can result in an additional 10%–20% reduc-
tion in LDL-C levels (Bays et al 2004; Stein et al 2004). 
The recently published EXPLORER study investigated the 
efﬁ  cacy and safety of rosuvastatin (40 mg) alone or in com-
bination with ezetimibe (10 mg) in 469 patients at high risk 
of CHD. After 6 weeks of therapy, signiﬁ  cantly more patients 
receiving rosuvastatin/ezetimibe than rosuvastatin alone 
achieved ATP III LDL-C cholesterol goals (100 mg/dL, 
94.0% vs 79.1%, p  0.001) and the optional LDL-Cl goal 
(70 mg/dL) for very high-risk patients (79.6% vs 35.0%, 
p  0.001). The combination of rosuvastatin/ezetimibe 
reduced LDL-C signiﬁ  cantly more than rosuvastatin (69.8% 
vs 57.1%, p  0.001) (Ballantyne et al 2007). While it is not 
yet clear whether this enhanced lipid reduction will translate 
into improved cardiovascular outcomes, a meta-analysis of 
statin and non-statin therapies showed similar improvement 
in CHD risk that correlated with levels of LDL-C reduction 
(Robinson et al 2005). Controlled clinical trials comparing 
outcomes with a combination of a statin and ezetimibe against 
statin monotherapy are underway.
Future directions
Statins have emerged as the global leader in pharmacologic 
therapy for dyslipidemia. As evidence supporting aggressive 
reductions in LDL-C continues to grow, the use of statins, 
especially second and third generation drugs, will continue 
to grow in parallel. The third generation statin, rosuvas-
tatin, has demonstrated reasonable clinical efﬁ  cacy and 
safety in several clinical trials and post-marketing analyses. Vascular Health and Risk Management 2008:4(2) 351
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Safety issues surrounding the use of high-potency statins 
remain of paramount concern. Recent studies support 
the concept that the degree of LDL-C reduction does not 
correlate with adverse events, but rather appears to be a 
dose-dependent phenomenon. A clear understanding of the 
guidelines regarding statin safety will be essential for physi-
cians managing patients with dyslipidemia.
In addition to reducing LDL-C levels, an emerging target 
of therapy is high-density lipoprotein cholesterol (HDL-C). 
A recent analysis of the TNT study demonstrated that in sub-
jects with LDL-C below 70 mg/dL, individuals in the highest 
quintile of HDL-C levels were are signiﬁ  cantly lower risk for 
major cardiovascular events as compared to those in the low-
est HDL-C quintile (p  0.03) (Barter et al 2007). These data 
suggest that in individuals achieving LDL-C goals with statin 
therapy, HDL-C may be an important target of therapy.
The effect of various agents on HDL-C was evaluated in 
the Comparative Effects on Lipid Levels (COMPELL) trial 
(Jones 2006). This study determined the relative efﬁ  cacy of 
combination therapy with a statin and niacin or ezetimibe 
compared with a statin alone over 12 weeks. Coadministra-
tion of niacin (500 mg up-titrated to 2000 mg) with atorvas-
tatin (20–40 mg, n = 60) or rosuvastatin (10–20 mg, n = 65) 
decreased LDL-C by 56% and 51% and increased HDL-C by 
22% and 24%, respectively (p = NS). While simvastatin plus 
ezetimibe decreased LDL-C by 57%, HDL-C only increased 
by 10% compared to baseline. Rosuvastatin (10–40 mg) 
monotherapy decreased LDL-C by 53% and raised HDL-C 
by 7%. Future studies involving rosuvastatin/fenoﬁ  brate 
combination therapy and the recently announced combination 
of rosuvastatin with a next generation fenoﬁ  brate (ABT-335) 
will provide further insight into the efﬁ  cacy of dual-targeted 
therapy on both LDL-C and HDL-C proﬁ  les.
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